10/02/2025
Important Update for Families
The MINT Program is pleased to announce that we can now provide Beyfortus (nirsevimab) to eligible infants. This protection is available for babies born after April 1, 2025 who are unable to access Beyfortus through their primary care provider.
Why is this important?
RSV (respiratory syncytial virus) is a very common and highly contagious respiratory infection. While many older children and adults experience it like a cold, RSV can cause serious illness in babies, leading to bronchiolitis, pneumonia, and sometimes hospitalization.
What is Beyfortus?
Beyfortus is a monoclonal antibody designed to provide babies with passive immunity against RSV. Unlike a vaccine, which helps the body build its own antibodies over time, Beyfortus delivers immediate protection that lasts through the RSV season. This is especially valuable for infants who are too young to be vaccinated or at higher risk of complications.
Families whose infants meet the criteria are invited to contact the MINT Program directly to book an appointment and learn more about this important preventative option.
Together, we can help protect our youngest community members from RSV. 💙